Abstract-Recently, we demonstrated that the heptapeptide angiotensin-(1-7) (Ang- [1] [2] [3] [4] [5] [6] [7] ) exhibits a favorable kinetic of nitric oxide (NO) release accompanied by extremely low superoxide (O 2 Ϫ ) production. In this report we describe AVE 0991, a novel nonpeptide compound that evoked effects similar to Ang-(1-7) on the endothelium. AVE 0991 and unlabeled Ang-(1-7) competed for high-affinity binding of [
A ngiotensin-(1-7) (Ang- [1] [2] [3] [4] [5] [6] [7] ), a biologically active component of the renin-angiotensin system, regulates blood pressure by counteracting the vasoconstrictor and proliferative effects of Ang II. 1 Ang-(1-7) was vasodilatory in many vascular beds, including canine 2 and porcine 3 coronary arteries, rat aorta, 4 and feline mesenteric arteries. 5 Chronic infusion of Ang-(1-7) in spontaneously hypertensive rats 6 and Dahl salt-sensitive rats 7 reduced mean arterial blood pressure. This antihypertensive effect could be the reason for the attenuated pressor response to Ang II and phenylephrine and the improved baroreceptor reflex function in spontaneously hypertensive rats in response to chronic infusion of Ang-(1-7). 8 The limited data concerning the effects of Ang-(1-7) on human vascular function are conflicting. Ang-(1-7) blocked the Ang II-induced vasoconstriction in isolated human arteries 9 and antagonized vasoconstriction in forearm circulation by Ang II infusion in normotensive men. 10, 11 Also, a direct vasodilation to the same extent in basal forearm circulation of both normotensive subjects and hypertensive patients caused by Ang-(1-7) was reported. 12 In contrast, Ang-(1-7) did not alter basal forearm blood flow in normotensive men 10, 11 and in patients with heart failure treated with an ACE inhibitor. 13 The vasodilator bradykinin (BK) appears to be involved in the vascular and antiproliferative effects of Ang-(1-7). 14, 15 There are two possibilities of interactions between BK and Ang- (1) (2) (3) (4) (5) (6) (7) . First is an induction of enhanced synthesis and/or release of endothelial kinins by Ang-(1-7) and second is a potentiation of the effects of BK and/or endogenous kinins by Ang-(1-7). According to the latter, it had been shown that preincubation of isolated coronary arteries with Ang-(1-7) increased the relaxation produced by BK. 16 -18 The same is true for the BK-induced blood pressure-lowering effect, which was potentiated by Ang-(1-7) in normotensive and hypertensive rats. 19, 20 There are several mechanisms that appear to be responsible for the BK-potentiating effects by Ang-(1-7). It appears to involve a receptor-mediated induction of nitric oxide (NO) release 2, 21, 22 and/or prostaglandins 23, 24 and endothelium-derived hyperpolarizing factor. 25 Although a specific Ang-(1-7) receptor has not been cloned yet, there are several sources of evidence that support its existence, based on binding studies with endothelial membrane 26 and functional studies showing the opposing and/or differential actions of Ang II and Ang-(1-7). 27 Furthermore, binding of Ang-(1-7) to ACE induces a cross-talk between BK receptors and ACE, leading to resensitization of BK B 2 receptors, 28 and binding of Ang-(1-7) to the ACE C-domain prevents to a certain extent the degradation of BK. 28, 29 The contribution of each of these mechanisms appears to be dependent on the vascular bed, the species, and on the investigated vessel diameter. 30 Recently, we have directly shown that Ang-(1-7) induces, through a kinin-mediated mechanism, a relatively slow release of bioactive NO from cultured endothelial cells. This NO release was associated with a concomitant, very low production of superoxide (O 2 Ϫ ) 21 as well as peroxynitrite and cytotoxic radicals. Consequently, a nonpeptide, orally active compound that mimics the favorable NO/O 2 Ϫ releasing profile of Ang-(1-7) might have significant therapeutic potential for the treatment of cardiovascular diseases associated with dysfunctional endothelium. This prompted us to initiate a program directed toward the synthesis and identification of a nonpeptide mimic of Ang-(1-7), which succeeded in the discovery of the compound AVE 0991, 5-formyl-4 -methoxy-2- (Figure 1 ). The in vitro results obtained with this agonist of the putative Ang-(1-7) receptor and their comparison to those elicited by Ang-(1-7) are described here.
Methods

Binding of [ 125 I]-Ang-(1-7)
Ang-(1-7) (Bachem) was radiolabeled with chloramine T and [ 
NO and O 2 ؊ Measurements
Primary cultures of BAECs grown to confluence in 6-well plates were used (200 to 250 g protein or 3ϫ10 Ϫ5 cells per well). 31, 32 After removal of the culture medium by aspiration, the monolayers were washed twice with 2 mL of warm (37°C) HEPES-Tyrode's solution, pH 7.4 (in mmol/L: KCl 2.7, NaCl 137, CaCl 2 1.8, MgCl 2 2, NaH 2 PO 4 0.36, glucose 5, HEPES 10). Thereafter, the cells were preincubated for 15 minutes at 37°C with 1 mL HEPES-Tyrode's solution containing 3-isobutyl-1-methyl-xanthine (IBMX, 100 mol/ L). IBMX was added to have incubation conditions, which were identical with those used for measurement of intracellular cyclic GMP in BAECs. 32 Compounds dissolved in HEPES-Tyrode's solution and superoxide dismutase (0.3 mol/L) were added at the concentrations and times indicated in the results.
Detection of NO by a porphyrinic nanosensor and its preparation were performed as previously described. 33, 34 The current, which is proportional to NO concentration, was measured by the porphyrinic sensor. The sensor operated in an amperometric (current proportional to NO concentration versus time) mode at a constant potential of 0.68 V versus a saturated calomel electrode (SCE). An amount of NO detected by the sensor was calculated on the basis of colorimetric measurements (integrated area under current-time curve). A microsensor capable of almost instantaneous indirect detection of O 2 Ϫ was prepared according to the general procedure described previously 35 and subsequently modified in our laboratory for single-cell measurements. 36 The O 2 Ϫ sensor consists of two electrodes: The first electrode is for detection of the total concentration of H 2 O 2 generated stoichiometrically by the fast dismutation of O 2 Ϫ by superoxide dismutase, and the second electrode is for the measurement of basal H 2 O 2 concentration. The difference between the currents generated by these two electrodes was used as an analytical signal for indirect O 2 Ϫ determination. Both microsensors operated at a potential of Ϫ0.23 V versus SCE. The O 2 Ϫ sensor was combined with the NO sensor in one unit (tandem sensor) of total diameter of Ϸ2 to 3 m. Two separate instruments (Gamry FAS1 femtostats) were used for the recording of NO and O 2 Ϫ .
Statistical Analysis
Values are expressed as meanϮSEM from 3 to 5 experiments, with a value of PϽ0.05 considered statistically significant. Statistical evaluation was done by ANOVA followed by an unpaired Student t test. All analyses were made with the statistical software, Microcal Origin. 
Results
Specificity of AVE 0991
AVE 0991 was void of significant inhibition of the specific binding in the selected panel of 25 pharmacologically relevant receptors (eg, 11% and 12% inhibition at AT 1 and AT 2 receptors, respectively) or significant inhibition of the control activity in 5 enzymes at the tested concentration of 10 mol/L AVE 0991.
NO and O 2 ؊ Production in Primary Cultured BAECs
Two seconds after injection of AVE 0991 (10 mol/L), a gradual increase of NO concentration was observed. The rate of NO increase was 13.9Ϯ0.1 nmol/L/s, and maximum concentration of 295Ϯ20 nmol/L (nϭ5) was reached after Ϸ20 seconds. NO release was accompanied after a delay of 18Ϯ0.3 seconds by a slow release of O 2 Ϫ (0.75Ϯ0.1 nmol/L/s), with a maximum concentration of 18Ϯ2.0 nmol/L (nϭ5) (Figure 2a) .
In comparison to AVE 0991, Ang-(1-7) (10 mol/L) evoked an almost identical peak concentration of NO release (270Ϯ25 nmol/L). The rate of Ang-(1-7)-stimulated NO was fast (180 nmol/L/s), (Figure 2b) . Also, the rate of O 2 Ϫ release (16Ϯ3.0 nmol/L/s) was faster than that observed for AVE 0991, but the peak concentration was not significantly different. However, the duration of NO release was much shorter than that observed for AVE 0991. Therefore, the amount of NO released (by colorimetric measurement) after stimulation with Ang-(1-7) was Ϸ5 times lower than that measured for AVE 0991 (Figure 3 
Discussion
The present study demonstrated that the new nonpeptide compound AVE 0991 is able to evoke effects on endothelial cells similar to that observed for heptapeptide Ang- (1-7) .
AVE 0991-stimulated NO release from cultured BAECs is due to the activation of endothelial NO synthase (eNOS). This is supported by the fact that the production of NO was significantly inhibited by the L-arginine analogue L-NMMA. The amount of AVE 0991-stimulated NO production was Ϸ5 times higher than that stimulated by Ang- (1-7) , but the respective EC 50 values of AVE 0991 and Ang-(1-7) for NO release were in a similar range (2.1Ϯ3.0 and Ϸ3 mol/L, 21 respectively). The release of NO from eNOS of endothelial cells is always concomitantly accompanied by the release of superoxide. 37 The O 2 Ϫ production, in turn, is related to the kinetics of NO release. 38, 39 A favorable kinetic is characterized by a slower rate of NO release. The rate of NO release by AVE 0991 was relatively slow, which led to a very small generation of O 2 Ϫ . In comparison, a fast rate of NO release stimulated by calcium ionophore A23187, bradykinin, or acetylcholine generates an O 2 Ϫ concentration several times higher than that observed for AVE 0991. The main source of O 2 Ϫ production was inhibited by L-NMMA, similar to that observed for NO. Moreover, the similar EC 50 values for both NO and O 2 Ϫ generation by AVE 0991 are due to an Ang-(1-7)-mediated stimulation of eNOS. The process of O 2 Ϫ production by eNOS is triggered by a rapid consumption of local L-arginine (substrate of eNOS).
A specific receptor for Ang-(1-7) has not been cloned yet. However, several functional and receptor binding studies provide evidence for the existence of a unique Ang-(1-7) receptor, distinct from AT 1 and AT 2 receptors. 27 We could confirm the data of Tallant et al 26 , which is able to block some of the biological effects of Ang-(1-7), 27 totally competed with the specific binding of [
125 I]-Ang-(1-7) on BAECs, as also shown by Tallant et al. 26 However, [D-Ala 7 ]-Ang-(1-7) failed to completely block (Ϸ50% inhibition only) NO release stimulated by AVE 0991 or Ang-(1-7). 21 According to the specificity of AVE 0991 versus Ang II receptors, we observed a significant reduction of AVE 0991-stimulated NO release by EXP 3174 and even more pronounced by PD 123,177 (Ϸ50% and 90%, respectively). This significant but not completely inhibitory effect of EXP 3174 and PD 123,177 in the AVE 0991-stimulated NO release are in line with our findings on the Ang-(1-7)-stimulated NO release 21 but in contrast to previous results from Broshnihan, 22 which revealed any inhibitory efficacy of AT 1 and AT 2 receptor antagonists on the Ang-(1-7)-mediated NO release. However, our observed incomplete inhibition of the AVE 0991-mediated NO release on BAECs, together with the results of our binding experiments, are in favor of the previous suggestion that the Ang-(1-7) as well as the AVE 0991 effects could be mediated by non-AT 2 PD 123,177-sensitive and non-AT 1 EXP 3174 -sensitive Ang II binding sites. 21, 22, 26 Although eNOS activity appears to be the source of both NO and O 2 Ϫ production, the influence of the Ang II antagonists on the AVE 0991-induced O 2 Ϫ productions was quite different from their effects on the respective NO production. PD 123,177 had no significant effect on O 2 Ϫ production, whereas EXP 3174 was void of any inhibitory efficacy. In addition, the inhibitory effect of [D-Ala 7 ]-Ang-(1-7) on O 2 Ϫ production was weaker (Ϸ35% inhibition) when compared with the respective inhibition of NO production. At present, these different influences of the Ang II antagonists on NO and O 2 Ϫ production cannot be explained. The moderate NO release by AVE 0991 was associated by a low concomitant production of O 2 Ϫ . Since it is suggested that generation of O 2 Ϫ and subsequent fast reaction between O 2 Ϫ and NO to form peroxynitrite and cytotoxic radicals play a role in endothelial dysfunction and vascular injury, the nonpeptide AVE 0991 has a similar NO/O 2 Ϫ releasing profile to Ang-(1-7) and might be a valuable compound for the preservation of the functional vascular system.
Perspectives
After the recent clinical findings described by Zeiher et al 40 and Heitzer et al, 41 endothelial dysfunction is confirmed as a prognostic marker and will probably be recognized in the near future as a unique cardiovascular disease. The discovery of the nonpeptide and orally active Ang-(1-7) agonist AVE 0991 as a potent mimic of the unique NO/O 2 Ϫ -releasing profile of Ang-(1-7) opens the venue toward a novel treatment of patients with endothelial dysfunction.
